ADX71149: Phase IIa started

In June, Johnson & Johnson's Janssen Pharmaceuticals Inc. unit began a double-blind, placebo-controlled, international Phase IIa trial evaluating 25-150 mg oral ADX71149 twice daily for 8 weeks as an ...